Profile
David C.
Dalgarno is the founder.
He founded Theseus Pharmaceuticals, Inc. in 2017 and served as the Chief Technical Officer from 2018 to 2022.
Dr. Dalgarno also held the position of Scientist at Schering-Plough Corp.
and Vice President-Research Technologies at ARIAD Pharmaceuticals, Inc. from 1992 to 2017.
Dr. Dalgarno obtained undergraduate and doctorate degrees from the University of Oxford.
Former positions of David C. Dalgarno
| Companies | Position | End |
|---|---|---|
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2017-05-31 |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | - |
| THESEUS PHARMACEUTICALS, INC. | Founder | - |
Training of David C. Dalgarno
| University of Oxford | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- David C. Dalgarno
